Prognostic significance of polo-like kinases in @entity995 : correlation with XXXX outcome, clinical and histopathological parameters.

@entity1 @entity5 @entity9370 @entity995 @entity3 @entity17861
BACKGROUND: @entity995 is evolving, but it is still a therapeutic challenge for pediatric oncologists. Polo-like kinases (PLKs) plays an important role in cell cycle events. They play a crucial role in cell proliferation which may lead to @entity5 formation. The objective of this study is to investigate the role of @entity9370 and @entity17861 proteins in @entity1 @entity995 tissues. DESIGN: Non-randomized, prospective study was performed in the Dr R. P. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India. @entity1 : This study included 74 primary enucleated @entity995 tissues. METHODS: Expression of @entity9370 and @entity17861 protein were assessed in primary enucleated @entity995 tissues by immunohistochemistry and western blotting. MAIN OUTCOME MEASURES: Expression of @entity9370 and @entity17861 protein were correlated with clinical and histopathological parameters, @entity5 staging and overall survival of @entity1 . RESULTS: Immunohistochemical results revealed expression of @entity9370 in 47/74 (63.51%) cases and @entity17861 in 31/74 (41.89%) cases. Western blotting confirmed the immunoreactivity results. Expression of @entity9370 showed correlation with poor differentiation and @entity5 invasion. In addition, @entity9370 was statistically significant with massive @entity3 , whereas @entity17861 did not correlate with any of the clinical or histopathological parameters. There was no statistical correlation in the overall survival of @entity1 with @entity9370 and @entity17861 expression. CONCLUSIONS: @entity9370 expression was associated with poor @entity5 differentiation and histopathological high-risk factors. These proteins may be involved in tumorigenesis and progression of disease. These results suggest that @entity9370 may act as a potential therapeutic target and a promising marker for developing potent small molecule inhibitors of PLK isoforms in @entity995 .
